NEW HAVEN, Conn., Feb. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following February investor conferences.
BIO CEO & Investor Conference (February 6-9, 2023)
Presentation Date/Time: Tuesday, February 7 at 10:45 a.m. ET
Corporate presentation: Farrell Simon, SVP, Head of Commercial and Strategy
Meeting participation: Lisa Delfini, CFO, and Farrell Simon, SVP, Head of Commercial and Strategy
Location: New York, NY and virtual
SVB Securities Global Biopharma Conference (February 13-16, 2023)
Presentation Date/Time: Tuesday, February 14 at 11:20 a.m. ET
Corporate presentation: Jennifer Good, President and CEO, and Lisa Delfini, CFO
Location: Virtual
A live webcast of the SVB Securities Global Biopharma Conference corporate presentation will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the audio webcast will also be available on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. The Company reported statistically significant results from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in adults with IPF. Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.42 |
| Daily Change: | -0.13 -1.72 |
| Daily Volume: | 2,138,778 |
| Market Cap: | US$903.460M |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
